Co-expression of the SARS-CoV-2 entry receptors ACE2 and TMPRSS2 in healthy human conjunctiva.
ACE2
COVID-19
Conjunctival epithelial cells
Human conjunctiva
Immunohistochemistry
SARS-CoV-2
TMPRSS2
Western blot
Journal
Experimental eye research
ISSN: 1096-0007
Titre abrégé: Exp Eye Res
Pays: England
ID NLM: 0370707
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
15
12
2020
revised:
10
02
2021
accepted:
22
02
2021
pubmed:
6
3
2021
medline:
21
4
2021
entrez:
5
3
2021
Statut:
ppublish
Résumé
The purpose of this study was to evaluate the expression of the SARS-CoV-2 receptors ACE2 and TMPRSS2 in an immortalized human conjunctival epithelial cell line and in healthy human conjunctiva excised during ocular surgery, using Western blot, confocal microscopy and immunohistochemistry. The Western blot showed that ACE2 and TMPRSS2 proteins were expressed in human immortalized conjunctival cells, and this was confirmed by confocal microscopy images, that demonstrated a marked cellular expression of the viral receptors and their co-localization on the cell membranes. Healthy conjunctival samples from 11 adult patients were excised during retinal detachment surgery. We found the expression of ACE2 and TMPRSS2 in all the conjunctival surgical specimens analyzed and their co-localization in the superficial conjunctival epithelium. The ACE2 Western blot levels and immunofluorescence staining for ACE2 were variable among specimens. These results suggest the susceptibility of the conjunctival epithelium to SARS-CoV-2 infection, even though with a possible interindividual variability.
Identifiants
pubmed: 33667466
pii: S0014-4835(21)00092-0
doi: 10.1016/j.exer.2021.108527
pmc: PMC7921718
pii:
doi:
Substances chimiques
RNA
63231-63-0
Peptidyl-Dipeptidase A
EC 3.4.15.1
Serine Endopeptidases
EC 3.4.21.-
TMPRSS2 protein, human
EC 3.4.21.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108527Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Lancet Respir Med. 2020 Jul;8(7):687-695
pubmed: 32386571
Int J Biol Macromol. 2019 May 15;129:267-280
pubmed: 30726749
J Med Virol. 2020 Jun;92(6):589-594
pubmed: 32100876
PLoS One. 2020 Nov 5;15(11):e0241661
pubmed: 33151999
Ocul Surf. 2020 Jul;18(3):360-362
pubmed: 32289466
JAMA Ophthalmol. 2020 May 1;138(5):575-578
pubmed: 32232433
J Med Virol. 2020 Oct;92(10):2081-2086
pubmed: 32374427
Cornea. 2020 Dec;39(12):1556-1562
pubmed: 32826650
Ocul Surf. 2021 Jan;19:322-329
pubmed: 33176215
JAMA Ophthalmol. 2020 Oct 8;:
pubmed: 33034620
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Ocul Immunol Inflamm. 2020 Jul 3;28(5):735-738
pubmed: 32589459
J Pathol. 2020 Jul;251(3):228-248
pubmed: 32418199
Lancet. 2020 Feb 22;395(10224):e39
pubmed: 32035510
Ocul Surf. 2021 Jan;19:190-200
pubmed: 32502616
Ocul Surf. 2021 Jan;19:249-251
pubmed: 32991984
Int J Mol Sci. 2018 May 25;19(6):
pubmed: 29799444
Ocul Surf. 2020 Oct;18(4):537-544
pubmed: 32544566
Mol Syst Biol. 2020 Jul;16(7):e9610
pubmed: 32715618
Eye (Lond). 2020 Jul;34(7):1212-1219
pubmed: 32382146
New Microbiol. 2020 Oct;43(4):149-155
pubmed: 33135085
Cardiovasc Res. 2020 Aug 1;116(10):1733-1741
pubmed: 32638018
Nat Med. 2020 May;26(5):681-687
pubmed: 32327758
Exp Eye Res. 2020 Dec;201:108269
pubmed: 32980315